Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Oprozomib (Primary)
- Indications Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 14 Dec 2017 Planned End Date changed from 1 Feb 2018 to 31 Aug 2018.
- 14 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 30 May 2018.
- 14 Jul 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.